Press Release

View printer-friendly version
<< Back
Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call

AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced plans to host its fourth quarter and full year 2018 financial results and corporate highlights conference call and live webcast on Thursday, March 7, 2019 at 4:30 p.m. ET.

Conference Call & Webcast Details

To access the live conference call, please dial +1 (877) 709-8155 from the United States or +1 (201) 689-8881 internationally. A replay of the call will be available through March 14, 2019 by dialing +1 (877) 660-6853 from the United States or +1 (201) 612-7415 internationally. The conference call ID is 13688006.

To access the live and archived webcast of the presentation, please visit the Presentation & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.

About Aeglea BioTherapeutics

Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas.

Media Contact:

David Calusdian
Sharon Merrill Associates
617.542.5300
AGLE@investorrelations.com

Investor Contact:

Joey Perrone
Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com

LOGO-AEGLEA-RGB_small.jpg

Source: Aeglea BioTherapeutics, Inc.